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DNA is the molecular target for many of the drugs that
are used in cancer therapeutics. Of particular interest
are the minor groove binders, a group of DNA interac-
tive agents that bind to specific regions of the genome
and show significant toxicity towards cancer cells [1].
Alkylating agents induce permanent DNA damage and
exhibit potent antitumor activity. A range of alkylating
agents is known including monoalkylating and bifunc-
tional alkylating drugs. The latter were found to cross-
link the two complementary strands of DNA, which
usually results in more efficacious agents.
New chiral 1H,3H-pyrrolo[1,2-c]thiazoles were synthe-
sized and screened for their in vitro activity as antican-
cer agents in three human tumor cell lines, colorectal
adenocarcinoma, melanoma and breast adenocarcinoma.
(R)-6-Hydroxymethyl-5-methyl-3-phenyl-1H,3H-pyrrolo
[1,2-c]thiazole and the corresponding benzylcarbamate
showed selectivity for breast cancer cell lines with IC50
values of 2.4 μMa n d2 . 2μM, respectively. The latter
also showed significant activity against colorectal adeno-
carcinoma cancer cell lines (IC50 =8 . 7μM). In contrast,
the 7-hydroxymethyl-5-methyl-3-phenyl-1H,3H-pyrrolo
[1,2-c]thiazole gave moderate anticancer activity. The
performance against breast cancer cell lines (IC50 =1 . 0
μM) of a potential bisalkylating agent, a (3R)-6,7-bis
(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazole, wasn’t
significantly different from the one observed for the
monoalkylanting derivatives indicating that the main
mechanism of action may in fact be the monoalkylation
process.
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